Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice

Olanzapine (OLZ), a widely used second-generation antipsychotic drug, is known to cause metabolic side effects, including diabetes and obesity. Interestingly, OLZ-induced metabolic side effects have been demonstrated to be more profound in females in human studies and animal models. Metformin (MET)...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Sang Bum, Lee, Nayoung, Kim, Jaedeok, Kim, Saeha, Jang, Sooyeon, Park, Jong Kook, Lee, Keunwook, Choi, Soo Young, Kwon, Hyung-Joo, Lee, Chan Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596779/
https://www.ncbi.nlm.nih.gov/pubmed/36313357
http://dx.doi.org/10.3389/fphar.2022.906717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596779/
https://www.ncbi.nlm.nih.gov/pubmed/36313357
http://dx.doi.org/10.3389/fphar.2022.906717

Ejemplares similares